Exchange Transfusion in Pathology - PPT Pointer Guide (with Medicine Integration)

Slide 1 - Title Slide

• Exchange Transfusion: Pathological Basis and Clinical Integration
• Subtitle: Blood Banking / Transfusion Medicine + Clinical Pathology
• Include: definition box - "The removal of a patient's blood and simultaneous replacement with donor blood, removing pathological substances while restoring normal hematological function"

Slide 2 - Definition and Principles

• Exchange transfusion = removal of patient's blood + simultaneous replacement with donor blood
• Two types:
  • Simple (manual) exchange - push-pull technique through umbilical catheters
  • Automated Red Cell Exchange (RCE/apheresis) - machine-mediated, more precise
• Goal: Remove offending substance (e.g., HbS, bilirubin, antibody-coated RBCs) without raising hematocrit/viscosity
• Two-blood-volume exchange replaces ~85% of patient's circulation
  • Henry's Clinical Diagnosis and Management by Laboratory Methods

Slide 3 - Pathological Basis: Why Exchange Transfusion?

• Three core pathological mechanisms driving the need:
  1. Hyperbilirubinemia - unconjugated bilirubin neurotoxicity (kernicterus)
  2. Sickling pathology - HbS polymerization causing vaso-occlusion
  3. Immune hemolysis - maternal alloantibody-mediated RBC destruction in the newborn
• Exchange addresses all three: removes bilirubin, replaces HbS-bearing cells, clears antibody-coated cells
• Canalicular mechanisms for bilirubin excretion are immature in neonates - exchange bypasses this immaturity
  • Harrison's Principles of Internal Medicine 22E

Slide 4 - Indication 1: Neonatal Hyperbilirubinemia (HDN)

• Unconjugated (indirect) bilirubin exceeds albumin-binding capacity
• Free bilirubin crosses blood-brain barrier - binds basal ganglia, hippocampus, brainstem nuclei
• Results in bilirubin encephalopathy (BIND) / kernicterus

• TSB >25 mg/dL (generally accepted threshold) - Henry's
• Serum bilirubin >20 mg/dL (classic teaching) - Lee's Essential Otolaryngology
• Immediate exchange if signs of acute bilirubin encephalopathy:
  • Hypertonia, arching, retrocollis, opisthotonos, fever, high-pitched cry
  • OR if TSB ≥5 mg/dL ABOVE the phototherapy line on nomogram
• Risk factors warranting lower threshold: Isoimmune hemolytic disease, G6PD deficiency, asphyxia, significant lethargy, temperature instability, sepsis, acidosis
  • The Harriet Lane Handbook, 23rd ed.

• CBC, reticulocyte count, peripheral smear, bilirubin, Ca²+, glucose, total protein
• Blood type, direct Coombs test, newborn screen
• Post-exchange blood has NO diagnostic value - save pre-exchange sample
  • The Harriet Lane Handbook

Slide 5 - Indication 2: Hemolytic Disease of the Fetus and Newborn (HDFN)

• Maternal alloantibodies (IgG) cross the placenta and coat fetal RBCs
• Extravascular hemolysis by fetal/neonatal macrophages
• Common antibodies: Anti-D (most significant), Anti-K, Anti-c, Anti-E, Anti-Fy^a, Anti-Jk^b
• Duffy antibodies capable of severe HDN
  • Quick Compendium of Clinical Pathology

• Positive DAT (direct Coombs): IgG+, IgG+/C3+
• DAT pattern in HDN: IgG+ (or IgG+/C3-)
  • Quick Compendium of Clinical Pathology
• Peripheral smear: spherocytes, polychromasia, nucleated RBCs

• Large-volume or exchange transfusion for infants who did NOT receive intrauterine transfusion (IUT)
• Treatment: intrauterine and intravascular fetal transfusion, IVIG, plasma exchange
  • Henry's, Tintinalli's Emergency Medicine

• In isoimmune hemolytic disease: IVIG 0.5-1 g/kg may reduce need for exchange
  • The Harriet Lane Handbook

Slide 6 - Blood Product Selection for Neonatal Exchange

• Fresh (<5 days old); if unavailable, consider washed
• Irradiated (prevents transfusion-associated GVHD - TA-GVHD)
• Group O (universal donor for neonates)
• Negative for any active maternal antibody (e.g., anti-D)
• CMV-safe: seronegative OR leukoreduced (risk-reduced) for preemies <1200 g or for intrauterine transfusion
  • Quick Compendium of Clinical Pathology, 5th ed.

• RBCs reconstituted with compatible plasma to Hct 45%
• For large-volume transfusion, fresh RBCs (<10 days old) preferred
  • Henry's Clinical Diagnosis and Management

• Large-volume exchange transfusion is an indication for irradiated blood
• TA-GVHD risk in neonates (especially premature/low birth weight)
• TA-GVHD: presents 2-50 days post-transfusion with rash, diarrhea, fever, liver dysfunction, pancytopenia; >90% mortality
  • Henry's

Slide 7 - Procedure: Technique and Volume

• Route: Blood removed via Umbilical Arterial Catheter (UAC); infused via Umbilical Venous Catheter (UVC)
  • If UAC unavailable: peripheral arterial line or single venous catheter
• Volume: Two-blood-volume exchange (2 x 80 mL/kg = ~160 mL/kg in neonates)
• Expected outcomes:
  • Reduces total bilirubin by ~25%
  • Reduces fetal red cell mass by ~70%
• Exchange aliquots:
  • Full-term infants: 15 mL aliquots
  • Premature/less stable infants: 2-3 mL/kg/min (slower, to avoid hemolysis)
    • The Harriet Lane Handbook, 23rd ed.

Slide 8 - Indication 3: Sickle Cell Disease (SCD)

• HbS polymerizes under deoxygenated conditions - RBC sickling
• Sickled cells cause vaso-occlusion, hemolysis, organ damage
• Exchange goal: reduce HbS% without raising hematocrit (avoids hyperviscosity)

1. Stroke (most common)
2. Retinal artery occlusion
3. Splenic sequestration crisis
4. Acute chest syndrome (ACS) - multifactorial, infection, hypoxia, pulmonary vaso-occlusion; 20-50% of SCD patients; mortality 2-14%
5. Aplastic crisis
6. Fulminant priapism (>6 hours, unresponsive to medical management)
7. Preoperative (high-risk surgery: cardiac surgery - exchange preferred over simple transfusion)

• Quick Compendium, Goldman-Cecil Medicine, Henry's

• Children with abnormal transcranial Doppler velocity (stroke prevention)
• Progressive renal, cardiopulmonary disease
• Complicated pregnancy
• Target HbS <30% in children; <50% in adults
  • Quick Compendium

Slide 9 - Red Cell Exchange by Apheresis vs Simple Transfusion (SCD)

• Simple transfusion (Hb >9 g/dL) equally effective as exchange for low- and moderate-risk surgery
• High-risk (cardiac) surgery: exchange preferred
  • Goldman-Cecil Medicine, Henry's

Slide 10 - Indication 4: Other Indications

• Babesiosis (severe): Exchange transfusion is treatment for severe parasitemia - removes infected RBCs
  • Treatment: clindamycin + quinine + exchange transfusion - Medical Microbiology 9e
• Malaria (hyperparasitemia - though now less commonly used)
• Polycythemia in newborns: Venous Hct >65% - partial exchange transfusion to reduce viscosity
  • The Harriet Lane Handbook
• Hyperleukocytosis (acute leukemia): Leukapheresis or exchange transfusion only if symptomatic leukostasis
  • The Harriet Lane Handbook
• Lead/heavy metal poisoning (severe): Hemodialysis, peritoneal dialysis, or exchange transfusion may be indicated
  • Roberts and Hedges' Clinical Procedures in Emergency Medicine
• Renal failure (historical - ESRD context)
  • Brenner and Rector's The Kidney

Slide 11 - ASPEN Syndrome (Pathology Complication - High Yield)

• Full form: Association of Sickle cell disease, Priapism, Exchange transfusion, and Neurologic events
• Timing: Within 11 days of exchange transfusion in SCD
• Presentation: Headache, seizures, altered mental status, hemiparesis
• Pathophysiology: Abrupt elevation in hematocrit → decreased cerebral blood flow; release of vasoactive substances from penile detumescence
• Management: Aggressive treatment → complete neurologic recovery in most cases
• Prevention: Monitor closely during/after RCE for priapism
  • Quick Compendium of Clinical Pathology, Henry's

Slide 12 - Complications of Exchange Transfusion

• Emboli, thromboses
• Hemodynamic instability
• Electrolyte disturbances - especially hypocalcemia (citrate accumulates → chelates Ca²+)
• Coagulopathy (dilutional)
• Infection (catheter-related)
• Death (rare)
  • The Harriet Lane Handbook

• TA-GVHD (prevented by irradiation)
• Alloimmunization (especially in multiply transfused SCD patients)
  • Most common alloantibodies: anti-K, C, E, Fy^a, Jk^b
  • Overall alloimmunization rate 19-47% without phenotype matching
  • Reduced to 0.5%/unit with Cc, D, Ee, Kell matching
    • Quick Compendium
• Hypothermia (from cold blood products - prevent with warming devices)
• Hypocalcemia from citrate (supplement calcium when transfusion rate >100 mL/min)

Slide 13 - Monitoring and Pre/Post Exchange Parameters

• CBC + differential, reticulocyte count
• Peripheral smear
• Total/direct bilirubin
• Ionized calcium, glucose
• Total protein / albumin (calculate B/A ratio)
• Blood type and Coombs (DAT/IAT)
• Newborn metabolic screen
• Save for serologic / genetic studies if indicated
  • The Harriet Lane Handbook

• Monitor QTc (hypocalcemia)
• Hemodynamic monitoring
• Aliquot-based exchange (15 mL/full-term; 2-3 mL/kg/min for premature)

Slide 14 - Alloimmunization in Transfused Patients (Pathology Deep Dive)

• SCD patients chronically transfused develop alloantibodies against foreign RBC antigens
• Alloimmunization rate: 19-47% without phenotypic matching
• Most common alloantibodies formed: anti-K, anti-C, anti-E, anti-Fy^a, anti-Jk^b
• With extended phenotype matching (Cc, D, Ee, Kell): rate reduced from 3% to 0.5% per unit transfused
• Clinical importance: future crossmatch difficulties, delayed hemolytic transfusion reactions, HDFN in pregnancies
  • Quick Compendium of Clinical Pathology, 5th ed.

Slide 15 - Recent Evidence (Medicine Integration via PubMed)

• De Winter et al. 2023 (PMID 36469119) - History and current standards of postnatal management in HDFN; reviewed indications and outcomes of exchange transfusion vs IVIG
• Chastain et al. 2024 (PMID 39259272) - Updated guideline on managing neonatal hyperbilirubinemia; emphasizes phototherapy thresholds and when to escalate to exchange
• Wickremasinghe & Kuzniewicz 2025 (PMID 40619190) - Neonatal hyperbilirubinemia review (Pediatric Clinics, 2025) - latest evidence on exchange thresholds
• STOP and STOP II Trials (referenced in Henry's): Exchange transfusion / chronic RBC transfusion reduces first stroke incidence in SCD children with high-risk transcranial Doppler; stopping transfusion leads to return of stroke risk within 4.6 months

Slide 16 - Summary Table: Exchange Transfusion Quick Reference

Recommended References for PPT Citations

1. Quick Compendium of Clinical Pathology, 5th ed. (Sections 2.3.1.2-2.3.1.3, 2.5.1.1)
2. Henry's Clinical Diagnosis and Management by Laboratory Methods (Neonatal & Pediatric Transfusion, RCE in SCD)
3. The Harriet Lane Handbook, 23rd ed. (Chapter 18)
4. Goldman-Cecil Medicine International Edition (SCD Management)
5. Harrison's Principles of Internal Medicine 22E (Bilirubin metabolism)
6. De Winter et al., Eur J Pediatr 2023 - PMID 36469119
7. Wickremasinghe & Kuzniewicz, Pediatr Clin North Am 2025 - PMID 40619190
8. STOP / STOP II trials (Adams et al., 1998; Adams & Brambilla, 2005)

• Use a Bhutani nomogram image on Slide 4 (bilirubin vs age in hours with risk zones and exchange line)
• Add the ASPEN syndrome flowchart on Slide 11 - examiners love this high-yield complication
• Include a blood product selection checklist visual on Slide 6
• The STOP trial data makes a strong clinical evidence slide (bar graph: 11 strokes standard care vs 1 in transfusion group)
• Keep Slide 8 (SCD indications) as a mnemonic: "SRSA-AP" - Stroke, Retinal artery occlusion, Splenic sequestration, ACS, Aplastic crisis, Priapism